Cargando…
Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life – A Case Study of the Innovative Medicines Initiative
Evidence from randomized controlled trials available for timely health technology assessments of new pharmacological treatments and regulatory decision making may not be generalizable to local patient populations, often resulting in decisions being made under uncertainty. In recent years, several re...
Autores principales: | Happich, Michael, Brnabic, Alan, Faries, Douglas, Abrams, Keith, Winfree, Katherine B., Girvan, Allicia, Jonsson, Pall, Johnston, Joseph, Belger, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540324/ https://www.ncbi.nlm.nih.gov/pubmed/32301116 http://dx.doi.org/10.1002/cpt.1854 |
Ejemplares similares
-
A comparison of reweighting estimators of average treatment effects in real world populations
por: Lin, Chen‐Yen, et al.
Publicado: (2021) -
Reweighting Parton Showers
por: Bellm, Johannes, et al.
Publicado: (2016) -
Event reweighting to account for DPA
por: Chierici, R, et al.
Publicado: (2001) -
Efficient Ensemble Refinement by Reweighting
por: Köfinger, Jürgen, et al.
Publicado: (2019) -
Temporal dynamics of normalization reweighting
por: Baker, Daniel H., et al.
Publicado: (2023)